ClinicalTrials.gg
CompletedNCT03573323IXORA-RUpdated Jul 28, 2020Results posted

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

A Phase 4 interventional study of Ixekizumab and Guselkumab in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 124 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-28.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,027
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
5th of 22
1,027 · median 156
Started
2018
the only one that year
Phase 4
6 of 22
3 open now
Registered
15th of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 6 in phase 4, and was the 15th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • biologic
  • biologic therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have chronic plaque psoriasis based on a diagnosis for at least 6 months before baseline as determined by the investigator.
  • Are a candidate for phototherapy and/or systemic therapy.
  • Have both an Static Physician Global Assessment (sPGA) score of ≥3 and a Psoriasis Area and Severity Index (PASI) score ≥12 at screening and at baseline.
  • Have ≥10% body surface area (BSA) involvement at screening and baseline.
  • If a male, agree to use a reliable method of during the study.
  • If female, agree to use highly effective method of contraception.

Exclusion criteria

Exclusion Criteria:

  • Predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis.
  • Have a history of drug-induced psoriasis.
  • Had a flare of psoriasis during the 12 weeks before baseline.
  • Use of tanning booths for at least 4 weeks before baseline.
  • Concurrent or recent use of any biologic agent within the following periods prior to baseline: etanercept \<28 days; infliximab, adalimumab, certolizumab pegol, or alefacept \<60 days; golimumab \<90 days; rituximab \<12 months; secukinumab \<5 months; or any other biologic agent (e.g., ustekinumab) \<5 half lives.
  • Have prior use of IL-23p19 antagonists (e.g., guselkumab, tildrakizumab, risankizumab), or have any condition or as addressed in the local labeling for guselkumab that would preclude the participant from participating in this protocol.
  • Have previously completed or withdrawn from this study, participated in any other study with ixekizumab or guselkumab, have participated in any study investigating IL-23p19 antagonists, or have received treatment with ixekizumab.
  • Have previously failed to respond to an IL-17 antagonist, per investigator assessment.
  • Have had a within 12 weeks of baseline.
  • Have a known allergy or to any biologic therapy.
  • Have had any major surgery within 8 weeks of baseline.
  • Have had a serious infection, have been hospitalized, or have received intravenous antibiotics for an infection within 12 weeks of baseline.
  • Are women who are pregnant, or who are lactating (breast-feeding).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,027 participants (actual)

Study arms

  • Experimental
    Ixekizumab

    A starting dose of 160 milligram (mg) of ixekizumab was given as 2 subcutaneous (SC) injections at Week 0. During the Induction Period, ixekizumab 80 mg was given every 2 weeks (Q2W) at Weeks 2, 4, 6, 8, 10, and 12. During the Extension Period, ixekizumab 80 mg was given as 1 SC injection (Q4W) every 4 weeks at Weeks 16 and 20. The Post Treatment Follow Up Period was for safety monitoring following the last treatment period.

    Drug: Ixekizumab

  • Experimental
    Guselkumab

    During the Induction Period, guselkumab 100 mg was given as 1 SC injection at Weeks 0, 4 and 12. 1 placebo injection (to maintain the blind) was given at Weeks 0, 2, 6, 8, and 10. During the Extension Period, guselkumab 100 mg was given at Week 20. 1 placebo injection (to maintain the blind) was given at Week 16. The Post Treatment Follow Up Period was for safety monitoring following the last treatment period.

    Drug: Guselkumab · Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY2439821

  • Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI 100)

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving PASI 75

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI scores compared to baseline.

    Time frame: Week 2

  2. Percentage of Participants Achieving PASI 90

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.

    Time frame: Week 4

  3. Percentage of Participants Achieving PASI 100

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

    Time frame: Week 4

  4. Percentage of Participants Achieving PASI 90

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.

    Time frame: Week 8

  5. Percentage of Participants Achieving Static Physician Global Assessment (sPGA) (0)

    The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.

    Time frame: Week 12

  6. Percentage of Participants Achieving PASI 50

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 50 were defined as having an improvement of at least 50% in the PASI scores compared to baseline.

    Time frame: Week 1

  7. Percentage of Participants Achieving PASI 100

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

    Time frame: Week 8

  8. Percentage of Participants Achieving PASI 100

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

    Time frame: Week 24

07

Results

Posted Jul 28, 2020

Participant flow

Blinded Treatment Period (Weeks 0-24)
Participant flow — Blinded Treatment Period (Weeks 0-24)
MilestoneIxekizumabGuselkumab
Started520507
Received at least one dose of study drug519506
Completed465459
Not completed5548
Withdrew: Screen failure11
Withdrew: Adverse event158
Withdrew: Protocol violation38
Withdrew: Withdrawal by subject179
Withdrew: Lack of efficacy23
Withdrew: Pregnancy12
Withdrew: Physician decision10
Withdrew: Lost to follow-up1413
Withdrew: Sponsor decision01
Withdrew: Alkaline phosphatase (alp) level reached01
Withdrew: Noncompliant to protocol procedures12
Post-Treatment Follow Up (Weeks 25-36)
Participant flow — Post-Treatment Follow Up (Weeks 25-36)
MilestoneIxekizumabGuselkumab
Started465456
Completed406399
Not completed5957
Withdrew: Withdrawal by subject2212
Withdrew: Lack of efficacy819
Withdrew: Physician decision43
Withdrew: Did not wish to return to study32
Withdrew: Discontinued trt and completed follow up148
Withdrew: Not compliant to protocol procedures811
Withdrew: Sponsor decision01
Withdrew: Repeat infections01

Outcome measures

PrimaryPercentage of Participants Achieving 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI 100)

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI 100)
percentage of participantsIxekizumabGuselkumab
Percentage of Participants Achieving 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI 100)41.3 (37.1 to 45.6)24.9 (21.1 to 28.6)
Statistical analysis
  • Ixekizumab vs Guselkumab · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Achieving PASI 75

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI scores compared to baseline.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 75
percentage of participantsIxekizumabGuselkumab
Percentage of Participants Achieving PASI 7522.9 (19.3 to 26.5)5.1 (3.2 to 7.0)
Statistical analysis
  • Ixekizumab vs Guselkumab · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Achieving PASI 90

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 90
percentage of participantsIxekizumabGuselkumab
Percentage of Participants Achieving PASI 9021.0 (17.5 to 24.5)7.9 (5.5 to 10.2)
Statistical analysis
  • Ixekizumab vs Guselkumab · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Achieving PASI 100

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 100
percentage of participantsIxekizumabGuselkumab
Percentage of Participants Achieving PASI 1006.7 (4.6 to 8.9)1.4 (0.4 to 2.4)
Statistical analysis
  • Ixekizumab vs Guselkumab · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Achieving PASI 90

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 90
percentage of participantsIxekizumabGuselkumab
Percentage of Participants Achieving PASI 9058.5 (54.2 to 62.7)35.9 (31.7 to 40.1)
Statistical analysis
  • Ixekizumab vs Guselkumab · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Achieving Static Physician Global Assessment (sPGA) (0)

The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) (0)
percentage of participantsIxekizumabGuselkumab
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) (0)41.9 (37.7 to 46.2)25.2 (21.5 to 29.0)
Statistical analysis
  • Ixekizumab vs Guselkumab · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Achieving PASI 50

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 50 were defined as having an improvement of at least 50% in the PASI scores compared to baseline.

Time frame:
Week 1
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 50
percentage of participantsIxekizumabGuselkumab
Percentage of Participants Achieving PASI 5027.5 (23.7 to 31.3)9.3 (6.7 to 11.8)
Statistical analysis
  • Ixekizumab vs Guselkumab · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Achieving PASI 100

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 100
percentage of participantsIxekizumabGuselkumab
Percentage of Participants Achieving PASI 10029.6 (25.7 to 33.5)13.6 (10.6 to 16.6)
Statistical analysis
  • Ixekizumab vs Guselkumab · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Achieving PASI 100

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 100
percentage of participantsIxekizumabGuselkumab
Percentage of Participants Achieving PASI 10050.0 (45.7 to 54.3)52.3 (47.9 to 56.6)
Statistical analysis
  • Ixekizumab vs Guselkumab · Cochran-Mantel-Haenszel · p = 0.414

Adverse events

Collected over Up to 48 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixekizumab0/519 (0%)18/519 (3.5%)113/519 (21.8%)
Guselkumab0/506 (0%)16/506 (3.2%)73/506 (14.4%)
Ixekizumab Post-Treatment Follow Up0/465 (0%)4/465 (0.9%)11/465 (2.4%)
Guselkumab Post-Treatment Follow Up0/456 (0%)4/456 (0.9%)9/456 (2%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventIxekizumabGuselkumabIxekizumab Post-Treatment Follow UpGuselkumab Post-Treatment Follow Up
Endometrial cancer stage ivNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1821/1930/1640/170
Myocardial infarctionCardiac disorders1/5192/5060/4650/456
CellulitisInfections and infestations0/5192/5060/4650/456
SyncopeNervous system disorders2/5190/5060/4650/456
Benign prostatic hyperplasiaReproductive system and breast disorders0/3370/3130/3011/286
Ventricular tachycardiaCardiac disorders0/5190/5060/4651/456
Joint dislocationInjury, poisoning and procedural complications0/5190/5060/4651/456
UreterolithiasisRenal and urinary disorders0/5190/5060/4651/456
Colitis ulcerativeGastrointestinal disorders0/5190/5061/4650/456
Crohn's diseaseGastrointestinal disorders1/5190/5061/4650/456
Most frequent other events
Most frequent other events
EventIxekizumabGuselkumabIxekizumab Post-Treatment Follow UpGuselkumab Post-Treatment Follow Up
Injection site reactionGeneral disorders49/5196/5060/4651/456
Upper respiratory tract infectionInfections and infestations40/51941/5066/4656/456
NasopharyngitisInfections and infestations34/51927/5065/4652/456

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)IxekizumabGuselkumabTotal
Mean49.0 ± 13.9049.0 ± 14.8849.0 ± 14.39
Sex: Female, Male
Sex: Female, Male(Participants)IxekizumabGuselkumabTotal
Female182193375
Male338314652
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IxekizumabGuselkumabTotal
Hispanic or Latino127120247
Not Hispanic or Latino383379762
Unknown or Not Reported10818
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IxekizumabGuselkumabTotal
American Indian or Alaska Native7613
Asian313566
Native Hawaiian or Other Pacific Islander224
Black or African American382967
White439431870
More than one race246
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)IxekizumabGuselkumabTotal
Canada103106209
United States417401818
08

Study locations

124 sites
  • Total Skin and Beauty Dermatology Center PC
    Birmingham, Alabama 35205, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Alliance Dermatology and Mohs Center
    Phoenix, Arizona 85032, United States
  • Perseverance Research Center
    Scottsdale, Arizona 85254, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • Bakersfield Dermatology and Skin Cancer Medical Group
    Bakersfield, California 93309, United States
  • Wallace Medical Group, Inc.
    Beverly Hills, California 90211, United States
  • California Dermatology and Clinical Research Institute
    Encinitas, California 92024, United States
  • Tien Q. Nguyen, MD inc. DBA First OC Dermatology
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Advanced Research Center
    Los Alamitos, California 90720, United States
  • Axis Clinical Trials
    Los Angeles, California 90036, United States
  • Dermatology Clinical Trials
    Newport Beach, California 92660, United States
  • Quest Dermatology Research
    Northridge, California 91324, United States
  • Northern California Research Corporation
    Sacramento, California 95821, United States
  • Advanced Research Center
    San Diego, California 92103, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • University Clinical Trials, Inc.
    San Diego, California 92123, United States
  • Synergy Dermatology
    San Francisco, California 94132, United States
  • Southern California Dermatology
    Santa Ana, California 92701, United States
  • Mosaic Dermatology
    Santa Monica, California 90403, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Unison Clinical Trials
    Sherman Oaks, California 91403, United States
  • Care Access Research-Walnut Creek
    Walnut Creek, California 94598, United States
  • Dermatology Physicians of Connecticut
    Shelton, Connecticut 06484, United States
  • Florida Academic Dermatology Centers
    Coral Gables, Florida 33134, United States
  • Olympian Clinical Research
    Largo, Florida 33770, United States
  • Suncoast Research Group, LLC
    Miami, Florida 33135, United States
  • Miami Dermatology & Laser Research
    Miami, Florida 33173, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Sensible Healthcare
    Ocoee, Florida 34761, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • International Clinical Research
    Sanford, Florida 32771, United States
  • MOORE Clinical Research
    Tampa, Florida 33609, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Olympian Clinical Research
    Tampa, Florida 33614, United States
  • Atlanta Dermatology, Vein Research Center, PC
    Alpharetta, Georgia 30022, United States
  • Skin Care Physicians of Georgia
    Macon, Georgia 31217, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • Dermatology Institute of Dupage Medical Group
    Wheaton, Illinois 60189, United States
  • Qualmedica Research LLC
    Evansville, Indiana 47715, United States
  • Dawes Fretzin Clinical Research
    Indianapolis, Indiana 46250, United States
  • Dermatology Specialists Research Indiana
    New Albany, Indiana 47150, United States
  • The Indiana Clinical Trials Center, PC
    Plainfield, Indiana 46168, United States
  • The South Bend Clinic
    South Bend, Indiana 46617, United States
  • Integrated Clinical Trial Services, Inc.
    West Des Moines, Iowa 50265, United States
  • Kansas City Dermatology, PA
    Overland Park, Kansas 66215, United States
  • Dermatology Specialist
    Louisville, Kentucky 40241, United States
  • Owensboro Dermatology Associates
    Owensboro, Kentucky 42303, United States
  • Lawrence J Green, M.D, LLC
    Rockville, Maryland 20850, United States
  • ActivMed Practices & Research, Inc
    Beverly, Massachusetts 01915, United States
  • Fivenson Dermatology
    Ann Arbor, Michigan 48103, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • Clarkston Skin Research
    Clarkston, Michigan 48346, United States
  • Henry Ford Medical Center- New Center One
    Detroit, Michigan 48202, United States
  • St Joseph Dermatology and Vein Clinic
    Saint Joseph, Michigan 49085, United States
  • Central Dermatology PC
    Saint Louis, Missouri 63117, United States
  • Impact Clinical Trials
    Las Vegas, Nevada 89106, United States
  • ActivMed Practices & Research, Inc
    Portsmouth, New Hampshire 03801, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Forest Hills Dermatology Group
    Forest Hills, New York 11375, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • Piedmont Plastic Surgery and Dermatology
    Charlotte, North Carolina 28277, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • PMG Research of Rocky Mount, LLC
    Rocky Mount, North Carolina 27804, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28411, United States
  • Bexley Dermatology Research
    Bexley, Ohio 43209, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Wright State Univ School of Medicine
    Fairborn, Ohio 45324, United States
  • Ohio State Univ College Of Medicine
    Gahanna, Ohio 43230, United States
  • Dermatologists of Southwest Ohio, Inc.
    Mason, Ohio 45040, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • Dermatology and Skin Surgery Center
    Exton, Pennsylvania 19341, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Yardley Dermatology
    Yardley, Pennsylvania 19067, United States
  • Clinical Partners LLC
    Johnston, Rhode Island 02919, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • International Clinical Research
    Murfreesboro, Tennessee 37130, United States
  • Arlington Research Center, Inc
    Arlington, Texas 76011, United States
  • Austin Institute for Clinical Research, Inc.
    Austin, Texas 78705, United States
  • Bellaire Dermatology
    Bellaire, Texas 77401, United States
  • Dermatology Treatment and Research Center
    Dallas, Texas 75230, United States
  • Modern Research Associates PLLC
    Dallas, Texas 75231, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Suzanne Bruce and Associates, PA
    Houston, Texas 77056, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Stephen L Miller, MD, PA
    San Antonio, Texas 78249, United States
  • University of Utah MidValley Dematology
    Murray, Utah 84107, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23502, United States
  • Virginia Dermatology & Skin Cancer Center
    Norfolk, Virginia 23502, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
  • National Clinical Research - Richmond
    Richmond, Virginia 23294, United States
  • Dermatology Associates
    Seattle, Washington 98101, United States
  • West Virginia Research Institute
    Morgantown, West Virginia 26505, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Dermatology Research Institute Inc.
    Calgary, Alberta T1Y 0B4, Canada
  • Kirk Barber Research
    Calgary, Alberta T2G 1B1, Canada

Showing the first 100 of 124 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Elewski BE, Blauvelt A, Gallo G, Wolf E, McKean-Matthews M, Burge R, Merola JF, Gottlieb AB, Guenther LC. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Dermatol Ther (Heidelb). 2022 Apr;12(4):911-920. doi: 10.1007/s13555-022-00704-2. Epub 2022 Mar 13. PubMed 35279805 ↗
  • Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K; IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021 Jun;184(6):1047-1058. doi: 10.1111/bjd.19509. Epub 2020 Oct 25. PubMed 32880909 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jul 2019, 8 months.

Results were first posted in Jul 2020, 1 year after primary completion.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 8 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2018
First posted
Jun 29, 2018
StartActual
Nov 9, 2018
Primary completionActual
Jul 15, 2019
CompletionActual
Jan 8, 2020
Results first posted
Jul 28, 2020
Last update
Jul 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03573323
Responsible party
Sponsor
First posted
Jun 29, 2018
Start date
Nov 9, 2018
Primary completion
Jul 15, 2019
Completion
Jan 8, 2020
Results posted
Jul 28, 2020
Last update
Jul 28, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixekizumab · Guselkumab

Start the discussion